Iradimed Corporation (NASDAQ:IRMD - Get Free Report)'s stock price hit a new 52-week high during trading on Wednesday . The company traded as high as $58.81 and last traded at $58.52, with a volume of 3401 shares trading hands. The stock had previously closed at $57.52.
Iradimed Price Performance
The company has a market cap of $744.92 million, a PE ratio of 40.26 and a beta of 0.81. The firm has a 50-day simple moving average of $54.60 and a two-hundred day simple moving average of $49.89.
Iradimed Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Monday, November 25th. Investors of record on Friday, November 15th were paid a $0.15 dividend. This represents a $0.60 annualized dividend and a yield of 1.02%. The ex-dividend date was Friday, November 15th. Iradimed's payout ratio is 41.10%.
Insider Buying and Selling at Iradimed
In other news, CFO John Glenn sold 2,500 shares of the business's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $54.18, for a total value of $135,450.00. Following the completion of the transaction, the chief financial officer now owns 4,383 shares of the company's stock, valued at $237,470.94. The trade was a 36.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 37.10% of the stock is owned by insiders.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Huntington National Bank boosted its holdings in shares of Iradimed by 51.3% during the third quarter. Huntington National Bank now owns 1,487 shares of the medical equipment provider's stock worth $75,000 after purchasing an additional 504 shares during the last quarter. Gladius Capital Management LP boosted its stake in Iradimed by 126.6% in the 3rd quarter. Gladius Capital Management LP now owns 1,727 shares of the medical equipment provider's stock worth $87,000 after buying an additional 965 shares during the last quarter. Quantbot Technologies LP boosted its stake in Iradimed by 83.0% in the 3rd quarter. Quantbot Technologies LP now owns 2,320 shares of the medical equipment provider's stock worth $117,000 after buying an additional 1,052 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Iradimed in the 3rd quarter valued at about $126,000. Finally, SG Americas Securities LLC acquired a new position in shares of Iradimed during the 3rd quarter valued at about $147,000. 92.34% of the stock is currently owned by institutional investors and hedge funds.
Iradimed Company Profile
(
Get Free Report)
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.
Recommended Stories
Before you consider Iradimed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Iradimed wasn't on the list.
While Iradimed currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
